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Abstract
Breast cancer metastasis to bone triggers a vicious cycle of tumor growth linked to osteolysis. Breast cancer cells and
osteoblasts express the epidermal growth factor receptor (EGFR) and produce ErbB family ligands, suggesting participation
of these growth factors in autocrine and paracrine signaling within the bone microenvironment. EGFR ligand expression
was profiled in the bone metastatic MDA-MB-231 cells (MDA-231), and agonist-induced signaling was examined in both
breast cancer and osteoblast-like cells. Both paracrine and autocrine EGFR signaling were inhibited with a neutralizing
amphiregulin antibody, PAR34, whereas shRNA to the EGFR was used to specifically block autocrine signaling in MDA-231
cells. The impact of these was evaluated with proliferation, migration and gene expression assays. Breast cancer metastasis
to bone was modeled in female athymic nude mice with intratibial inoculation of MDA-231 cells, and cancer cell-bone
marrow co-cultures. EGFR knockdown, but not PAR34 treatment, decreased osteoclasts formed in vitro (p,0.01), reduced
osteolytic lesion tumor volume (p,0.01), increased survivorship in vivo (p,0.001), and resulted in decreased MDA-231
growth in the fat pad (p,0.01). Fat pad shEGFR-MDA-231 tumors produced in nude mice had increased necrotic areas and
decreased CD31-positive vasculature. shEGFR-MDA-231 cells also produced decreased levels of the proangiogenic
molecules macrophage colony stimulating factor-1 (MCSF-1) and matrix metalloproteinase 9 (MMP9), both of which were
decreased by EGFR inhibitors in a panel of EGFR-positive breast cancer cells. Thus, inhibiting autocrine EGFR signaling in
breast cancer cells may provide a means for reducing paracrine factor production that facilitates microenvironment support
in the bone and mammary gland.
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Introduction
The epidermal growth factor (EGFR) has long been recognized
as a therapeutic target in breast and other epithelial cancers due to
its ability to potently stimulate cell proliferation, motility, and
invasion. The EGFR is activated by a family of ligands that
include epidermal growth factor (EGF), Amphiregulin (AREG),
transforming growth factor a (TGFa), heparin-binding EGF (HB-
EGF), betacellulin, epiregulin, epigen, and Neuregulin 2b [1].
These factors are synthesized as plasma membrane proteins
tethered by a transmembrane domain, requiring proteolytic
cleavage to be accessible to receptors [2]. These individual ligands
may induce differential signaling pathways downstream of the
EGFR, both from the plasma membrane and intracellular
compartments, which can result in certain ligands being more
efficient stimulators of proliferation [1,3,4,5,6]. Breast cancer cells
frequently express the EGFR, one or more of its ligands and
proteases that shed the ligands, resulting in autocrine signaling that
may contribute to their rapid growth and invasive behavior.
The EGFR is frequently expressed in the basal subtype of breast
cancer, which typically lack the expression of estrogen receptor a
(ERa), progesterone receptor (PR) and Her2 receptor, accounting
for only ,15–20% of the total disease [7,8,9]. However, 50–75%
of basal breast cancers express EGFR and are more aggressive
than similar tumors lacking the receptor [10,11]. Co-expression of
the ADAM17 protease and the TGFa ligand in primary basal
tumors has been associated with reduced survival [12]. These
observations suggest that more aggressive basal-like breast cancers
have the capacity to be stimulated by autocrine EGFR signaling,
whereas the ligands produced by other subtypes of breast cancer
(luminal, HER2 positive) may serve as paracrine signaling
molecules [13].
Models of breast cancer metastasis to specific organs have
provided evidence that EGFR ligands mediate paracrine signaling
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profiling of a bone-homing MDA-231 subline found that MMP-1
(matrix metalloproteinase 1) and ADAMTS-1 (a disintegrin and
metalloproteinase with thrombospondin motifs) were upregulated,
leading to increased AREG shedding [14]. The increased AREG
appeared to signal via the EGFR present on osteoblasts, leading to
reduced production of osteoprotegrin, the decoy ligand to the
major controller of osteoclast differentiation and activation,
receptor for nuclear factor kb ligand (RANKL) [14]. Increased
osteoclast numbers and activity is a key element in the growth of
breast cancer cells in the bone [15]. The metastatic growth of these
MDA-231 sublines could be inhibited by the EGFR-targeted
therapeutics cetuximab or gefitinib alone, or in combination with
other targeted agents [14,16,17].
Autocrine activation of EGFR on breast cancer cells may also
influence signaling with the bone microenvironment. Models of
bone metastasis have provided evidence that cancer cell activation
of EGFR often leads to the production of paracrine signaling
molecules necessary for survival and rapid growth within the bone.
Among the most well characterized factors that facilitate the
growth of cancer cells in the bone is parathyroid hormone related
protein (PTHrP), which signals through its receptor on osteoblasts,
and leads to an increase of RANKL expression and increased
osteoclast activity [18,19]. Autocrine activation of EGFR is a
major regulator of PTHrP in both breast and lung cancers [20].
Intriguingly, the stimulation of the PTH receptor on osteoblasts
stimulates the expression and shedding of AREG, thus potentially
initiating a second autocrine loop of EGFR signaling in osteoblasts
[21,22]. Taken together, autocrine EGFR-driven cytokine pro-
duction, as well as paracrine interactions of the EGFR ligands
themselves, both appear to drive growth of bone-metastatic lesions
suggesting various agents that disrupt this signaling could be
effective treatments for breast cancer metastasis to bone.
In this study, we evaluated EGFR ligand expression by a bone-
homing subline of the human breast cancer cell line MDA-231,
with regard to their impact on specific malignant phenotypes and
breast cancer cell signaling, as well as paracrine signaling to a
mouse bone cell line. To specifically inhibit autocrine signaling in
the MDA-231 cells we reduced EGFR expression by a lentiviral
shRNA, and to inhibit both autocrine and paracrine EGFR
signaling, an AREG neutralizing antibody was used. Finally, we
evaluated the impact of altered autocrine and paracrine signaling
on MDA-231 cell growth in vitro as well as in vivo, in the bone and
mammary fat pad.
Materials and Methods
Ethics Statement
Animal care and experiments were approved by the Indiana
University Animal Care and Use Committee (IACUC), OLAW
assurance #94094-01, protocol #10-014.
Cell lines and cell culture
MDA-MB-231 cells were obtained from T. Guise [18] and
MC3T3 cells were obtained from A. Robling [23], and were
grown in DMEM (Sigma, St Louis, MO) supplemented with 10%
FBS (Atlanta Biologicals, Lawrenceville, GA) and 10 ng/mL
insulin (Sigma). S1T3 and NS2T2A1 cells were both obtained
from Z. Bouizar [24], and grown in a 50:50 mixture of RPMI and
DMEM:F12 (Sigma) supplemented with 10% FBS. SUM149 cells
were purchased from Asterand (Detroit, MI) and grown in F12
Hams (Sigma) supplemented with 10% FBS (Atlanta Biologicals).
Production of shEGFR-MDA-231 and shControl cells: MDA-
MB-231 cells [18] were plated in 12-well dishes and grown to 50%
confluence. 10 mL of either EGFR shRNA lentiviral particles
(Santa Cruz Biotechnology, Santa Cruz, CA) or Control shRNA
lentiviral particles (Santa Cruz Biotechnology) with 6 mg/mL
polybrene (Santa Cruz Biotechnology) was added to the wells.
Cells were grown for 24 hours before removal of lentiviral
particles, then grown another 24 hours before 1.5 mg/mL
puromycin selection. Pooled colonies were tested for EGFR
expression by western blotting, and cultures maintained in media
with 1. 5 mg/mL puromycin.
Animal injections and therapeutic dosing
For intratibial inoculation, either 7.5610
3 MDA-MB-231,
shEGFR-MDA-231, or shControl cells were inoculated into the
left tibia of 3–4 week old female athymic nude mice (Harlan,
Indianapolis, IN). Mice were anesthetized with 5% isoflurane and
laid in a dorsal position. Autoclaved 100 mL Hamilton syringes
with 27 gauge needles were used to puncture the skin at the
proximal end of the left tibia. The syringe was gently pushed
through the epiphysis to about 3 mm deep to assure it passed the
through metaphysis, and 10 mL of cell suspension was inoculated
slowly over 20 seconds. Mice were anesthetized with 5%
Isoflurane, and lay in a prone position for weekly radiography to
monitor lesion progression (35 kV for 10 seconds; Faxitron,
Lincolnshire, IL). Animals were x-rayed at 26 magnification,
and lesions were first detected at 14 days post inoculation. End
point for these studies was 4–6 weeks after tumor inoculation, or
earlier if the size of the x-ray lesion reached 25% of the upper tibia
area, swelling of knee region exceeded 2-fold the diameter of the
non-injected limb, the limb could not be used for ambulation, or
the animals displayed signs of excessive pain, per our veterinarian-
guided animal protocol and pain-scale. Osteolytic area on x-ray
was measured using ImageJ software (NIH).
Upon sacrifice, hind limbs were removed and fixed in 10%
neutral buffered formalin for 48 hours, and then 70% EtOH for at
least 24 hours. After microCt imaging, bones were decalcified
(10% EDTA for 1 week), and embedded in paraffin. Tibiae were
sectioned at 7 mM in the sagittal plane and mid-sagittal sections
were stained with hematoxylin and eosin (H&E) or tartrate
resistant acid phosphatase (TRAP). TRAP staining for osteoclasts
was performed using an azo-dye coupling method with fast red
violet LB salt (F-3881, Sigma) as described [25]. After rehydration
through graded alcohols, sections were incubated in freshly
prepared TRAP stain at 37uC for 15 minutes, counterstained in
hematoxylin, and mounted in glycerin jelly. Serial slides were
stained with hematoxylin and eosin (H&E) as described [26]. For
this study, PAR34 antibody was administered for 4 weeks through
intraperitoneal injection once weekly at 10 mg/kg in a sterile 0.9%
saline solution [27].
For mammary fat pad tumors, shControl or shEGFR-MDA-
231 cells were combined with 50% Matrigel and inoculated at
1610
6 cells in 100 ml total volume in the first mammary fat pad of
female athymic nude mice, aged 3–4 weeks (Harlan). One group
of shControl mice was administered PAR34 at 10 mg/kg/week by
intraperitoneal injection. Tumors were measured twice weekly for
length (L) and width (W), and tumor volume (V) calculated as:
V=(L 6W
2)60.5.
Micro-CT
Fixed tibiae were scanned using a SkyScan micro-CT (SkyScan
1172; SkyScan, Belgium) as previously described [28], with the
following scanner settings: voltage, 60 kV; resolution, 6 mm;
0.5 mm aluminum filter; stage rotation, 0.7; and frame-averaging,
2. Flat-field corrections were used to minimize background noise.
NRecon software (SkyScan), was used to reconstruct the images,
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tibia. CTan software (SkyScan), was used to analyze reconstructed
images, separating bone from surrounding soft tissue with a
threshold range of 100 to 255 (binarized 0–255 scale). Bone
volume was reported from analysis of 700 sections per tibia. 3D
images were obtained using MeshLab software (MeshLab, 3D-
CoForm) with smoothing option.
Trabecular bone analysis regions were chosen in the secondary
spongiosum, with a consistent total length of 1 mm measured for
each tibia. Region of interest was chosen as only the internal bone
cavity containing trabecular bone with cortical bone excluded.
Osteoclastogenesis assays
Osteoclastogenesis assays were performed as in [29]. Briefly, 1–
4 month old mice were euthanized, hind limbs dipped in 70%
ethanol and removed at hip. Femur and tibia ends were cut to
expose the bone marrow cavity, and each marrow cavity flushed
with 5–10 mL of DMEM cell culture medium. 50 mL of cell
suspension was mixed with 450 mL of 2% acetic acid to lyse red
blood cells, and remaining cells counted. 4610
5 cells were plated
in each well of a 24-well dish with 60 ng/mL RANKL
(PeproTech) for 3 days. After 3 days, 2610
3 MDA-231, shControl,
or shEGFR-MDA-231 cells were plated with the bone marrow
cells, with 60 ng/mL RANKL and 10 ng/mL MCSF (PeproTech)
and grown for 3 days before TRAP staining. For TRAP staining,
cells were washed with 16PBS, fixed with ice cold methanol for
10 minutes, and stained in fresh TRAP solution for 15 minutes at
37uC. TRAP solution was replaced with 16PBS for cell counting
under the microscope.
Statistical analysis
Results of in vitro experiments are expressed as the mean 6 SD
of triplicate or quadruplicate measures of independent replicates
for single experiments. Results of in vivo experiments are expressed
as the mean 6 SEM of three to six replicates of samples taken
from ten individual animals. All statistical comparisons were based
on two-tailed analysis of the Student’s t test. A P value of ,0.05
was considered to be significant.
Results
Amphiregulin is highly secreted by MDA-231 cells
Previously we determined a subline of the aggressive breast
cancer cell line MDA-231 efficiently colonizes mouse bone after
intracardiac inoculation, expresses high levels of EGFR protein
and modest levels of the ErbB2 and ErbB3 receptors, and sheds
AREG [20]. To more completely evaluate EGFR ligand
production in these cells, we examined the expression of five
EGFR ligands, including epidermal growth factor (EGF), AREG,
betacellulin, heparin-binding EGF (HB-EGF), and transforming
growth factor a (TGFa) using ELISA for both conditioned media
and membrane extracts. MDA-231 cells release high levels of
AREG (0.048pM), and maintain similar concentrations associated
with the membrane fraction. Surprisingly, higher levels of HB-
EGF also remained associated with the cell membrane (0.254pM),
with lower levels (0.008pM) detectable in the media (Fig. 1A). Low
concentrations of TGFa were present on the membrane fraction
(0.008pM) while higher levels were detected in the media
(0.063pM). Betacellulin was present in low concentrations
(0.004pM) and EGF protein was undetectable using this
methodology (Fig. 1A). In terms of autocrine signaling in vitro,
AREG appears to be shed at the highest concentrations, while
high levels of membrane-associated HB-EGF indicate that this
could be the predominant ligand if it were cleaved from the
membrane.
Amphiregulin activates EGFR phosphorylation on both
MDA-231 and MC3T3 cells
To determine if the impact of EGFR signaling in the bone
microenvironment is similar to that of breast cancer cells, we used
a mouse preosteoblastic cell line MC3T3 as a model to compare
receptor phosphorylation induced by exogenous ligand treatment.
Here, we used 100 nM recombinant human ligands (AREG,
TGFa, and HB-EGF), as well as recombinant human EGF
(10 nM) to serve as the prototype ligand. MC3T3 or MDA-231
cells were treated with EGF, AREG, TGFa, or HB-EGF, followed
by western blotting with their respective phospho-specific
antibodies. Modest levels of basal EGFR tyrsosine phosphorylation
could be detected in MDA-231 cells at Y992 and Y1086, whereas
baseline EGFR levels could not be detected in the MC3T3 line
with any of the phospho-specific antibodies (Fig. 1B). Human EGF
and HB-EGF were able to induce receptor phosphorylation on
both MDA-231 and MC3T3 cells, as detected with 4G10, a pan
phosphotyrosine antibody, as well as the other site-specific
antibodies. Exogenous AREG induced modest phosphorylation
of some residues in MDA-231 cells compared to EGF, but
appeared to increase phosphorylation of all tested residues in
MC3T3 cells. We noted that TGFa caused very little phosphor-
ylation in the human cells and was not able to induce detectable
changes in EGFR phosphorylation in mouse MC3T3 cells.
Though both AREG and TGFa are shed and capable of inducing
receptor phosphorylation in MDA-231 cells, AREG appears to be
the highest cleaved ligand and it is able to potently activate the
EGFR on mouse osteoblast-like MC3T3 cells providing the
rationale to target this ligand as the main inducer of both
autocrine breast cancer signaling and paracrine receptor signaling
in mouse tissues.
shRNA to the EGFR causes a decrease in migration and
PTHrP expression in MDA-231 cells
To inhibit breast cancer cell autocrine and paracrine signaling,
we used shRNA to the EGFR as well as a monoclonal antibody
(PAR34) (Figure S1). To reduce autocrine EGFR signaling in the
MDA-231 line, cells were transduced with a lentiviral shRNA to
the receptor (shEGFR-MDA-231 cells) or a shRNA scrambled
control (shControl). As detected by western blot, there was a 64%
knockdown of the EGFR as compared to MDA-231 or shControl
cells, and this knockdown not affect levels of other EGFR family
receptors (Fig. 2A). Introduction of the shEGFR construct had no
effect on production of AREG, TGFa, or HB-EGF mRNA
production (data not shown). We verified by ELISA that ligand
protein levels were not disrupted by the shEGFR construct, as
AREG, TGFa, and HB-EGF were present in the media or on cell
membranes at the same levels in shEGFR-MDA-231 cells, as
compared to MDA-231 and shControl cells (Fig. 2B). Treatment
of MDA-231 or shControl cells with PAR34 antibody or control
IgG had no effect on ligand expression of AREG, TGFa, or HB-
EGF (Fig. 2B). As expected, a decrease (p,0.05) in PTHrP levels
in the shEGFR-MDA-231 cells was observed as compared to
control cells (Fig. 2C), indicative of reduced autocrine EGFR
signaling.
We then examined impact of PAR34 on breast cancer cells
grown in vitro. PAR34 inhibited exogenous AREG-induced
phosphorylation of tyrosines 992 and 1173 in MDA-231 cells,
when compared to IgG control (Figure S2B), and this inhibition
was AREG-specific, as PAR34 did not inhibit stimulation by EGF.
Reduced EGFR in Breast Cancer Cells
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non-tumorigenic, epithelial breast cell line S1T3 (S1 cells).
To further test the impact of autocrine EGFR signaling
inhibition by PAR34 antibody and shRNA knockown, cell
proliferation and migration were examined in vitro. EGFR
signaling has been reported to stimulate motility, but does not
induce proliferation in MDA-231 cells [30,31]. Using the MTT
assay we found that shEGFR-MDA-231 cells and controls treated
with PAR34 proliferated at a similar rate to non-treated controls
(Fig. 2C). As shown in Figure 2D, PAR34 inhibited migration
(p,0.001) of both MDA-231 and shControl cells by 20%, and
migration was decreased (p,0.001) by 65% in shEGFR-MDA-
231 cells relative to controls. Taken together, these in vitro assays
confirm that inhibition of EGFR by PAR34 or shRNA decreases
breast cancer cell motility.
PAR34 treatment modifies the trabecular patterning
factor of bone
To examine the impact of inhibiting AREG signaling within the
bone, we first evaluated PAR34 antibody treatment in non-tumor
bearing animals. Female athymic nude mice aged 3–4 weeks
received intraperitoneal injections of PAR34, at 10 mg/kg/week,
for 4 weeks. Upon sacrifice, tibiae were removed and prepared for
microCT and histological sectioning. While PAR34 treatment did
not affect the gross bone structure, as analyzed by both x-ray and
microCT (data not shown), microCT showed a decrease
(p,0.001) in trabecular pattern factor in PAR34 tibiae when
compared to vehicle treated animals (Table S1 and Figure S2A).
We also evaluated osteoclasts present in the newly deposited bone
under the hypertrophic zone of growth plate chondrocytes, and
observed an increase (p,0.01) in the number of these cells per
Figure 1. EGFR ligand expression and shedding in MDA-231 cells. (A) ELISA measurement of media or membrane extracts from MDA-231
cells. Measurements were taken from two independent cultures and performed in triplicate. (B) Western blots of anti-EGFR and anti-phosphorylated
tyrosine resides in MDA-231 or MC3T3 cells treated with EGF, AREG, TGFa, or HB-EGF.
doi:10.1371/journal.pone.0030255.g001
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30255Figure 2. Characterization of the shEGFR-MDA-231 cell line. (A) Extracts from MDA-231, shControl, and shEGFR-MDA-231 cells, probed with
anti-EGFR or anti-ErbB2, ErbB3, or ErbB4 antibodies and anti-b-Tubulin (loading control). Histogram notes relative pixel density of EGFR protein of
shEGFR-MDA-231 cells versus shControl and MDA-231 cells. (B) AREG, TGFa, and HB-EGF ELISA measurements of MDA-231, shControl, and shEGFR-
MDA-231 cells, to verify no changes in basal or PAR34 treated ligand expression. ELISA measurements were performed in triplicate from two separate
cultures. (C) Relative PTHrP mRNA levels in the shControl and shEGFR-MDA-231 cell lines. PTHrP was measured by qRT-PCR analysis and relative ratios
of PTHrP mRNA to GAPDH mRNA levels were shown (mean of triplicate measures from a single experiment; bars, SD). (D) MTT proliferation assays
were performed on shEGFR-MDA-231, MDA-231, and shControl cells, as well as PAR34-treated MDA-231 or shControl cells. MTT measurements were
performed in quadruplicate, p,0.05. (E) 24 hour migration assay of shEGFR-MDA-231, MDA-231, and shControl cells, with PAR34 treatment to the
latter two lines, p,0.001. Migrated cells were obtained from two separate migration wells, with four random fields chosen for counts from each well.
doi:10.1371/journal.pone.0030255.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30255Figure 3. In vivo analysis of autocrine or paracrine inhibition of EGFR. (A) Representative end point x-rays for each treatment group (top
row), with arrows denoting osteolytic lesion areas. Corresponding 3D micro-CT images (bottom row). n=10 animals per treatment group. (B) Kaplan-
meyer survival curve demonstrating significant increased survival in the shEGFR-MDA-231 injected animals, p,0.001. n=10 animals per group. (C)
Osteolytic lesion area was measured using ImageJ software from x-ray images. n=10 mice, p,0.01. PAR34-treated animals required sacrifice at the 3-
week time point due to maximum allowable lesion areas and pain scale (per our animal protocol). (D) Micro-CT bone volume analysis of tibiae in all
treatment groups. 700 sections were analyzed per tibia. p=not significant.
doi:10.1371/journal.pone.0030255.g003
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animals (Figure S2B and Table S1). Overall, PAR34 treatment
influenced bone growth, thus validating this dose and schedule as
effective for targeting bone in vivo.
shEGFR-MDA-231 cells produce smaller tumors in bone
To examine global inhibition of AREG signaling, or to
specifically reduce cancer cell EGFR signaling during osteolytic
lesion growth within the bone, female athymic nude mice (aged 3–
4 weeks) were inoculated in the left tibia with MDA-231,
shControl, or shEGFR-MDA-231 cells. Intratibial inoculation
was chosen to insure that differential motility of the shEGFR-
MDA-231 did not inhibit colonization of the bone. Three days
after inoculation, treatment of one group of MDA-231 inoculated
mice was initiated with weekly intraperitoneal injection of PAR-34
antibody (10 mg/kg). The MDA-231, shControl, and PAR34
treated groups had extensive osteolytic lesion destruction as
detected by x-ray and microCT at the experimental end-point,
while the majority of shEGFR-MDA-231 mice had smaller regions
of distinct bone loss measured by x-ray (Fig. 3A). All PAR34
treated animals required sacrifice after the 3-week time point, as
they displayed experimental end-point criterion including maxi-
mum x-ray lesion size, swelling of the injected limb, or ambulation
difficulties. Survival was increased (p,0.001) in shEGFR-MDA-
231 tumor-bearing mice as compared to those inoculated with
MDA-231 or shControl (Fig. 3B), and osteolytic lesion size was
decreased (p,0.01) in shEGFR-MDA-231 animals (Fig. 3C).
Although large lesions were readily apparent in the reconstruction
of microCT scans from the MDA-231, shControl, or PAR34
groups, total tibia head bone volume was not significantly different
as compared to the shEGFR-MDA-231 group (Fig. 3D).
Examination of H&E stained tibiae from all groups verified
large, destructive tumors within the MDA-231, PAR34 treated,
and shControl groups (Materials and Methods S1). Interestingly,
shEGFR-MDA-231 animals had smaller tumors (p,0.01) that
remained within the bone marrow cavity (Fig. 4A). Surprisingly,
the PAR34 treated animals had a larger tumor volume (p,0.05)
when compared to controls (Fig. 4B). Tartrate resistant acid
phosphatase (TRAP) staining indicated the number of osteoclasts
per tumor bone interface in shEGFR-MDA-231 bones trended
toward a decrease in comparison to MDA-231 or shControl
tumor-bearing tibiae (Fig. 4C). Additionally, we observed an
increase in osteoclasts per tumor bone interface, though this was
not significant (Fig. 4C).
Thus, it appears that decreased EGFR was sufficient to reduce
the size of osteolytic lesions and tumor volume within bone.
Conversely, PAR34 antibody enhanced MDA-231 growth within
the bone.
Figure 4. Histomorphometric analysis of tumor bearing bones. (A) Representative images of H&E stained tibiae from each treatment group.
Tumor region outlined in white, BM=bone marrow, T=Tumor. (B) Histomorphometric tumor volume analysis on H&E stained tibia sections. Care was
taken to measure the same size tissue volume on each section. *p,0.05 and **p,0.01. (C) Osteoclast counts of TRAP stained slides from each
treatment group. p=not significant, n=10 mice per group.
doi:10.1371/journal.pone.0030255.g004
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osteoclastogenesis in vitro
We also examined the effects of EGFR knockdown or PAR34
treatment using an in vitro osteoclastogenesis assay, whereby MDA-
231 or shEGFR-MDA-231 cells were co-cultured with mouse
bone marrow (BM) to determine if osteoclast formation could be
increased. As seen in Figure 5A, co-culture of BM with shEGFR-
MDA-231 cells stimulated fewer (p,0.01) osteoclasts than control
cell co-cultures, correlating with the decreased osteolytic lesion size
in vivo.
Next we evaluated the impact of PAR-34 and exogenous AREG
on various permutations of the co-culture assay. We also observed
that PAR34 antibody caused an increase in osteoclasts in BM
alone (Fig. 5B, p,0.01) or co-cultures with MDA-231 (p,0.01)
and the shEGFR-MDA-231 cells (p,0.001) (Fig. 5C&5D). In
contrast, exogenous AREG ligand failed to increase osteoclasts in
BM, but stimulated the formation in co-cultures that contained
MDA-231 cells (Fig. 5C, p,0.01). Intriguingly exogenous ligand
did not increase osteoclast number in the shEGFR-MDA-231
containing co-cultures (Fig. 5D). The impact of PAR-34 on BM
alone or cancer cell co-cultures generally corresponded with in vivo
findings where the antibody treatment produced increased
osteoclasts in non-tumor bearing bones and increased tumor size
in cancer cell injected bones.
To further investigate the impact of EGFR signaling inhibitors
on osteoclastogenesis, BM and MDA-231 co-cultures were treated
with a range of concentrations of gefitinib, a small molecule EGFR
inhibitor [32]. As shown in Figure S3, 1 mM gefitinib also
increased osteoclasts (p,0.001) in co-cultures, but showed a trend
toward decreased formation in BM cultures alone. These findings
coupled with those from PAR-34 treatments suggest that different
EGFR inhibitors can have distinct impacts on osteoclastogenesis
and in some cases they may enhance it.
shEGFR-MDA-231 cells produce smaller mammary fat
pad tumors
To determine if the reduced growth of the shEGFR-MDA-231
cells in bone was specific to that microenvironment, we examined
the in vivo growth rate of mammary fat pad tumors produced by
shControl or shEGFR-MDA-231 cells. A group of shControl-
inoculated animals were treated with weekly intraperitoneal
injections of PAR34 (10 mg/kg). As shown in Figure 6, tumor
volume measures and final masses were decreased (p,0.01) in
shEGFR-MDA-231 tumors as compared to shControl
Figure 5. Activated osteoclast measurement by bone marrow and cancer cell co-culture. (A) Co-cultures of mouse bone marrow with
MDA-231, shControl, or shEGFR-MDA-231 cells were TRAP stained to identify active osteoclasts. Four random fields were counted from two separate
wells for each co-culture. **p,0.01. (B–D) Co-cultures of mouse bone marrow with MDA-231 cells, (C) bone marrow only, or (D) bone marrow with
shEGFR-MDA-231 cells were treated with AREG ligand, PAR34 antibody, Control IgG antibody, or a combination of ligand with antibody as noted.
Wells were TRAP stained to identify active osteoclasts, and four random fields were counted form two separate wells for each treatment. **p,0.01,
***p,0.001. (E) bone marrow only or co-cultured with MDA-231 cells were treated with 1 mM gefitinib or DMSO control for 3 days followed by TRAP
staining for active osteoclasts. ***p,0.001.
doi:10.1371/journal.pone.0030255.g005
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30255Figure 6. shEGFR-MDA-231 cells produce smaller tumors in the mammary fat pad. (A) Tumor volume measurement for mammary fat pad
tumors grown from injection of shControl, PAR34 treated shControl cells, or shEGFR-MDA-231 cells. PAR34 treated animals were administered 10 mg/
kg/week of PAR34 by intraperitoneal injection. Tumor measurements were taken three times per week. **p,0.01, n=6 mice per group. (B) Upon
sacrifice, tumor masses were assessed. **p,0.01, n=6 mice per group. (C) Paraffin-embedded tumors were stained with anti-CD31 antibody for
vessel formation (top row), black arrows denote areas of vessel staining. Ki67 staining (middle row) was examined for cellular proliferation. shEGFR-
MDA-231 tumors contained large regions of necrosis, as seen in Necrosis in the bottom row. T=tumor, N=necrotic region. No necrosis was observed
in shControl or PAR34 treated tumors. Vessel and proliferation counts, as well as percent changes of necrotic regions are noted in Table 1. n=6
animals per treatment group. Magnification bars, CD31 and Ki67=100 mm. Necrosis=1 mm.
doi:10.1371/journal.pone.0030255.g006
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tumor volume and mass, these results were not significant
compared to shControl tumors (Fig. 6A&6B). Histological analysis
revealed an increased (p,0.05) necrotic area in shEGFR-MDA-
231 tumors, despite unchanged cell proliferation as detected by an
anti-Ki67 antibody (Table 1). However, fewer vessels (p,0.001)
were stained by anti-CD31 antibody in the shEGFR-MDA-231
tumors than shControl cells (Table 1 and Fig. 6C). Thus, reduced
growth in vivo of the shEGFR-MDA-231 cells was observed in the
mammary fat pad, likely correlated with reduced vascularization
of the tumor.
Decreased EGFR signaling causes a reduction in
proangiogenic factor expression
To explore the molecular basis of the reduced vasculature of the
mammary fat pad tumors produced by shEGFR-MDA-231 cells,
we first examined changes in expression of vascular endothelial
growth factor (VEGF). Previous work has reported VEGF is
regulated in breast cancer cells by EGFR signaling [33], however
we observed no differences in control versus shEGFR-MDA-231
cells (Fig. 7A). Previous publications have noted that EGFR
signaling regulates macrophage colony-stimulating factor-1
(MCSF-1) expression in murine cancer cells [34]. MCSF-1 could
influence angiogenesis by recruiting macrophages or various
progenitors from the bone marrow, which could produce VEGF
or directly contribute to neoangiogenesis [35,36]. MCSF-1 levels
were lower (p,0.05) in shEGFR-MDA-231 cells when compared
to controls, as measured by ELISA (Fig. 7B).
To verify this finding is due to EGFR inhibition and not off
target effects of the shRNA construct, we examined MCSF-1 levels
in a panel of breast cancer cell lines following treatment with the
small molecule EGFR inhibitor PD153035 or PAR34. PD153035
reduced MCSF-1 secretion from the parental MDA-231 (p,0.01),
shControl (p,0.01), SUM149 (p,0.05), and the tumorigenic
epithelial breast cancer cell line NS2T2A1 (p,0.01) (Fig. 7C).
PAR34 decreased MCSF-1 levels in MDA-231, shControl and
NS2TA1 cells (p,0.05) in which AREG is the predominant
ligand, but not in SUM149 cells. We further evaluated the
shEGFR-MDA-231 and control cells for matrix metalloproteinase
9 (MMP-9), a protease that promotes angiogenesis by releasing
VEGF that is bound to extracellular matrix [37]. As shown in
Figure 7D, MMP-9 levels were markedly reduced in cell extracts
of shEGFR-MDA-231, as compared to shControl and MDA-231.
Also, PAR34 reduced expression of the protease in SUM149 and
NS2TA1 cell lines. PD153035 inhibition (6-hrs) had no effect on
MMP-9 levels. These findings suggest that autocrine EGFR
signaling regulates at least two proangiogenic factors in breast
cancer cell lines, and disruption of receptor signaling would be
predicted to reduce vascularization and decreased growth of
tumors.
Discussion
In this study, we found that reduced EGFR expression
decreased MDA-231 cell growth within bone and the mammary
gland. Previous studies suggested that EGFR signaling promotes
growth in vivo as part of paracrine relationships between breast
epithelia-derived cells and the microenvironment. The mammary
epithelium expresses both EGFR and its ligands EGF, TGFa, and
AREG, suggesting a potential for autocrine signaling [38,39];
however, elegant recombination experiments established that
mammary gland ductal outgrowth requires EGFR expression in
the fat pad, and AREG expression in the epithelium [39,40,41]. In
lung and brain metastasis models, epigen or HB-EGF expressed by
MDA-231 cells signal to the EFGR on endothelial cells to facilitate
colonization of these organs. In a model of bone metastasis, breast
cancer cell derived AREG is thought to signal to the osteoblast,
facilitating osteoclast formation and driving osteolytic destruction.
In contrast, autocrine EGFR signaling is typically associated with
proliferation of epithelial cancers [13]. Since the MDA-231 line
bears a mutation in K-ras, which activates the MAPK cascade the
major driver of mitogenesis downstream of the EGFR [30,31], this
line represented an ideal system for modulating receptor levels
without reducing cell proliferation. The shEGFR-MDA-231 cells
did not exhibit alterations in the expression of ligands or other
ErbB receptors, and had identical rates of proliferation as
compared to control lines (Fig. 2). Decreased EGFR expression
in the MDA-231 resulted in slower tumor growth in both the bone
and the mammary gland (Figs. 3 and 6). The shEGFR-MDA-
231cells produced smaller osteolytic lesions in vivo and induced the
formation of fewer osteoclasts in vitro relative to controls (Figs. 3
and 5). Consistent with a central role for the breast cancer cell
EGFR in the stimulation of osteoclastogenesis, the addition of
exogenous AREG to co-cultures containing shEGFR-MDA-
231cell failed to induce increased numbers of the bone resorbing
cells (Fig. 5). We conclude that autocrine EGFR signaling
contributes to MDA-231 tumor growth in bone and the mammary
gland independent of driving cancer cell proliferation.
There is a growing appreciation that EGFR signaling in
epithelial cancer cells stimulates the expression of many chemo-
kines, cytokines, growth factors, and receptors that facilitate
paracrine interactions with non-cancer cells of the tumor
microenvironment [20,42,43,44]. EGFR signaling controls the
expression of VEGF isoforms, which are pivotal factors that
control angiogenesis in many tumors [33,42,45]. We did not detect
differences in VEGF levels in the shEGFR-MDA-231 cells,
consistent with previous studies of MDA-231 sublines [46].
However, we did detect decreases in proangiogenic factors such
as MCSF-1 and MMP-9 in the shEGFR-MDA-231 cells, as well as
a panel of breast cancer cell lines treated with an EGFR tyrosine
kinase inhibitor or PAR-34. Reduced expression of MCSF-1 and
MMP-9 would likely influence the growth of the MDA-231 cells in
Table 1. Histological Tumor Analysis.
Necrosis Ki67 CD31
% Necrotic Tumor Area
(mm
2) Fold Increase Number Cells Fold Increase Mean Vessel Count % Reduction
MDA-231 16 N/A 3166N / A 2 2 63N / A
PAR34 19 1.2 3467 1.09 2062 9.1
shEGFR-MDA-231 29 1.9* 32611 1.03 762 68.2***
doi:10.1371/journal.pone.0030255.t001
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production of PTHrP would be expected to contribute to reduced
growth of the MDA-231 line in bone. Previously, it has been
shown that PTHrP antibody inhibition dramatically decreased the
number of osteoclasts per tumor bone interface, coupled with
decreased osteolytic lesion size [18]. Consistent with the reduction
of PTHrP, we observed a trend in reduction of osteoclasts in
shEGFR-MDA-231 inoculated tibiae; also, in vitro studies indicated
that shEGFR-MDA-231 cells generate fewer osteoclasts than
control MDA-231 cells (Fig. 5A). It is likely that the EGFR on
breast cancer cells controls the expression of many additional
cytokines and growth factors that mediate tumor cell-microenvi-
ronment interactions, both in primary tumors and sites of
metastasis.
Our attempt to block both autocrine and paracrine EGFR
signaling by antagonizing AREG interaction with its receptor,
using PAR34 antibody, produced surprising results. Given that we
had previously found that AREG was the major ligand controlling
PTHrP expression in MDA-231 cells [20], it was not surprising
that PAR-34 decreased MCSF-1 and MMP-9 production.
However, the antibody only modestly inhibited MDA-231 cell
motility in comparison to knockdown of the receptor (Fig. 2D).
Figure 7. MCSF-1 and MMP-9 decrease with EGFR inhibition. (A) anti-VEGF probed western blot for MDA-231, shControl, and shEGFR-MDA-
231 extracts, b-tubulin used for loading control. (B) Media was harvested from shControl or shEGFR-MDA-231 cells and analyzed for MCSF-1 by ELISA,
*p,0.05. Measurements were obtained from two separate cultures, and performed in triplicate. (C) MDA-231, shControl, SUM149, or NS2TA1 cells
were treated with the tyrosine kinase inhibitor PD153035 (10 mg/mL) compound for 6 hours or PAR34 (10 mg/mL) for 24 hours before media harvest
for MCSF-1 ELISA, *p,0.05 and **p,0.01. Measurements were obtained from two separate cultures, and performed in triplicate. (D) anti-MMP9
antibody probed western blots for shControl, MDA-231, SUM149, or NS2TA1 cell extracts treated with PD153035 (10 mg/mL) compound for 6 hours
or PAR34 (10 mg/mL) for 24 hours. shEGFR-MDA-231 cells were untreated. anti-b-tubulin used as loading control.
doi:10.1371/journal.pone.0030255.g007
Reduced EGFR in Breast Cancer Cells
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30255This raises questions as to whether the various ligands might
exhibit differential impacts on cell motility and growth factor
production, as previously established for some of these agonists in
the stimulation of EGFR-dependent cellular proliferation [3].
Also, the failure of the antibody to potently inhibit motility may
reflect its inability of block signaling of the EGFR from internal
compartments such as the endosome [47]. In vivo, we observed that
PAR-34 treatment increased MDA-231 tumor growth within the
bone, while also increasing active osteoclasts at the tumor bone
interface. Correspondingly, PAR34 increased osteoclastogenesis in
BM alone as well as BM cancer cell co-cultures, and increased
osteoclast numbers below the growth plate of non-tumor bearing.
These later findings suggest that PAR-34 may induce a higher
baseline bone turnover, and this could contribute to the increased
tumor growth that we observed in our in vivo experiments.
Although an impact on baseline osteoclastogenesis of BM cultures
was not observed with gefitinb, we found that this EGFR inhibitor
also increased osteoclastogenesis MDA-231 containing co-cultures.
Together these unanticipated findings lead us to speculate that
AREG-EGFR signaling in the bone marrow microenvironment
may influence other processes besides osteoblast differentiation
and subsequent osteoclastogenesis. Recent reports indicate that
EGFR signaling decreases hematopoietic stem cell mobilization in
response to G-CSF [48]. Derivatives of hematopoietic stem cells
include osteoclasts, monocytes, myeloid suppressor cells and
megakaryocytes that all could influence the growth of breast
cancer cells in the bone [49]. Our unexpected findings with AREG
antibody treatments of cancer cells in the bone marrow encourage
a more careful analysis of the impact of various inhibitors on
EGFR signaling on all cell types in the breast cancer bone
metastasis microenvironment.
In conclusion, EGFR knockdown in MDA-231 cells reduced
their motility and production of secreted factors that stimulate
osteolytic lesion growth and angiogenesis in vitro. In vivo, EGFR
knockdown in MDA-231 cells reduced tumor growth both in the
mammary fat pad and the bone. MDA-231 cells act as a model for
triple negative breast cancers, so these findings raise the possibility
that interventions that could reduce EGFR expression in triple-
negative breast cancer cells might provide therapeutic benefit to
patients with metastatic disease.
Supporting Information
Figure S1 Model of inhibition of autocrine and para-
crine EGFR signaling within the bone environment. (A) In
an unhibited situation, cancer cells produce and cleave AREG to
act in autocrine or paracrine signaling. Autocrine EGFR signaling
can activate the expression of paracrine factors such as PTHrP
that can directly stimulate the PTH receptor on osteoblasts and
this increases RANKL production and osteoclastogenesis. In
addition, stimulation of the PTH receptor induces AREG-EGFR
signaling on the osteoblast, leading to increased RANKL
accessibility and oteoclastogenesis. Finally cancer cell derived
AREG can stimulate the EGFR on the osteoblast in a paracrine
manner resulting in increased RANKL accessibility and oteoclas-
togenesis (B) shEGFR knockdown in cancer cells will decrease
autocrine signaling and AREG-EGFR signaling in the endosome,
in turn decreasing PTHrP levels. Decreased PTHrP secretion will
lead to decreased osteoblast RANKL production, and a decrease
in osteolysis. However this should not prevent cancer cell derived
AREG from stimulating the EGFR on osteoblasts. (C) PAR34
inhibition of AREG binding the EGFR on cancer cells will
decrease PTHrP secretion, and thus decrease RANKL production
by the osteoblast. PAR34 may also inhibit cancer cell and
autocrine AREG from stimulating the osteoblast EGFR thus
reducing RANKL accessibility and osteolysis.
(TIF)
Figure S2 PAR34 inhibition on bone environment. (A)
Female athymic nude mice aged 3–4 weeks were treated with
weekly intraperitoneal injection of PAR34 antibody at 10 mg/kg
or an equal volume of sterile 0.9% saline as vehicle. Left column,
parraffin-embedded tibiae were TRAP stained for active osteo-
clasts. Active osteoclasts were counted in the primary spongiosum
directly under the growth plate. Arrows denote positively stained
osteoclasts. Right column, microCT images were reconstructed
from the secondary spongiosum, and denote changes in trabecular
bone. For both TRAP staining and microCT analysis, n=10 mice
per group. Magnification bar=170 mm. (B) MDA-231 or S1 cells
were treated with AREG ligand with or without PAR34 antibody,
and compared to PAR34 inhibition with EGF ligand treatment.
Cell lysates were resolved on 8% SDS-PAGE gels before
membrane transfer and probed with the corresponding tyrosine
phosphorylated antibodies.
(TIF)
Figure S3 Gefitinib treatment of bone marrow co-
cultures. Mouse bone marrow (BM) was cultured alone or co-
cultured with MDA-231 cells followed by treatment with 0.5 mM,
1.0 mM, or 5 mM of EGFR kinase inhibitor gefitinib for three
days. Osteoclasts were counted after TRAP staining from three
random fields from two separate wells. *** p,0.001. & denotes all
cultured cells in wells were dead after 5 mM gefitinib treatment.
(TIF)
Table S1 MicroCT and histomorphometry measure-
ments of PAR34 treated, non-tumor bearing tibiae.
(TIF)
Methods S1 Supporting Materials and Methods.
(DOC)
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